Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IMPAX LABORATORIES, LLC

Home Clinical Trial Sponsors and OrganizationsIMPAX LABORATORIES, LLC

IMPAX LABORATORIES, LLC

30831 Huntwood Ave, Hayward, California, United States

Also known as:

impax generics

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

29

9 active

Approvals

10

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

11

37.9%

Phase 3

10

34.5%

Phase 2

7

24.1%

Phase 4

1

3.5%

Trial Status Distribution

Active, not recruiting

9

31.0%

Completed

19

65.5%

Recruiting

1

3.5%

Clinical Trials

Trials sponsored by this organization (29)

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Feb 2025220 participants

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

Oct 202335 participants

Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson's with motor fluctuations.

Active, not recruiting

Jan 2021510 participants

Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.

Active, not recruiting

Jan 2020510 participants

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

Active, not recruiting

Jul 2019300 participants

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

Active, not recruiting

Jun 2019300 participants

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

Active, not recruiting

May 2019300 participants

An open-label extension study of the safety and clinical utility of IPX203 in Parkinson’s Disease patients with motor fluctuations

Active, not recruiting

May 2019300 participants

Page 1 of 4

Approvals

Approvals by Agency

FDA

Food and Drug Administration

10

Approvals

Recent Approvals

Risedronate Sodium

Risedronate Sodium

MIDODRINE HYDROCHLORIDE

MIDODRINE HYDROCHLORIDE

Nadolol and Bendroflumethiazide

Nadolol and Bendroflumethiazide

News

No news articles found

On this page

Overview
Clinical Trials29
Approvals10
News

Back to Organizations